We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Breast cancer patients should not live without a HER-2/neu tissue result -- But how safe can they live with it?
- Authors
Lüftner, Diana
- Abstract
Since the approval of the monoclonal antibody trastuzumab for the treatment of metastatic breast cancer, the determination of the HER-2/neu tissue status has been the subject of a never ending methodological evaluation and discussion. With the efficacy of any kind of trastuzumab -based therapy depending directly on the extent of HER-2/neu over-expression in the tumor, only patients with undoubtedly high HER-2/neu content in the cell membrane will profit from this targeted therapy. Reassuring information about the concordance of HER-2/neu results between the core biopsy and the surgically removed tumor does not exclude further uncertainties about HER-2/neu tissue testing in breast cancer.
- Subjects
BREAST cancer; CANCER patients; THERAPEUTICS; CELL membranes; IMMUNOGLOBULINS; TRASTUZUMAB
- Publication
Wiener Klinische Wochenschrift, 2004, Vol 116, Issue 1/2, p3
- ISSN
0043-5325
- Publication type
Article
- DOI
10.1007/BF03040416